-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412

Benzinga·11/03/2026 18:38:57
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $416 to $412.